First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: The experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party

Bone Marrow Transplantation

Volumn 34, Issue 12, 2004, Pages 1033-1037

  Rosti, G ^a   De Giorgi, U ^a   Wandt, H ^b   Lioure, B ^c   Leyvraz, S ^d   Kolbe, K ^e   Papiani, G ^a   Ballardini, M ^f   Kulekci, A ^g   Demirer, T ^g  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b KLINIKUM NÜRNBERG   (Germany)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d Centre Coordonné d Oncologie   (Switzerland)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^g ANKARA UNIVERSITY   (Turkey)

Author keywords

Extragonadal germ cell tumor; Hematopoietic progenitor cell support; High dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN EDEMA; CANCER CLASSIFICATION; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; EUROPE; FEMALE; FEVER; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKEMIA; LIVER TOXICITY; MALE; MEDIASTINUM TUMOR; MYELODYSPLASIA; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; OTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RETROPERITONEAL TUMOR; SOLID TUMOR; STOMATITIS; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; SURVIVAL ANALYSIS;

EID: 19944370162     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704704     Document Type: Article

References (21)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
2. Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000; 60: 1475-1482.
3. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
4. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-1440.
5. Schmoll HJ. Extragonadal germ cell tumors. Ann Oncol 2002; 13 (Suppl 4): 265-272.
6. Bokemeyer C, Nichols CR, Droz J-P et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20: 1864-1873.
7. Mandanas RA, Saez RA, Epstein RB et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 1998; 21 569-576.
8. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-1180.
9. Rosti G, De Giorgi U, Salvioni R et al. Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patients. Cancer 2002; 95: 131-137.
10. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1983; 85: 1828-1835.
11. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-2552.
12. De Giorgi U, Rosti G, Papiani G et al. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor. Haematologica 2002; 87: 95-104.
13. Hartmann JT, Einhorn L, Nichols CR et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001; 19: 1641-1648.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Gratwohl A, Baldomero H, Demirer T et al. Hematopoietic stem cell transplantation for solid tumors in Europe. Ann Oncol 2004; 15: 653-660.
16. Kollmannsberger C, Nichols C, Bamberg M et al. First-line high-dose chemotherapy ± radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000; 11: 553-559.
17. Decatris MP, Wilkinson PM, Welch RS et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 2000; 11: 427-434.
18. Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993; 23: 213-218.
19. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456.
20. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
21. Hartmann JT, Nichols CR, Droz J-P et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002; 13: 1017-1028.